Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

Table 3 Association between Anti-Ro52/TRIM21 antibodies and disease severity (range, 0 to 4)

	Whole group (N = 963)		Anti-Ro52/TRIM21 antibody positive (n= 194)		Anti-Ro52/TRIM21 antibody negative (n= 769)		Odds ratio (95% CI) and Pvalues (Anti-Ro52/TRIM21 positive vs negative)
	Mean	SD	Mean	SD	Mean	SD
General	0.89	1.22	1.16	1.41	0.82	1.16	1.23 (1.09, 1.39)	0.0061
Skin	1.25	0.68	1.23	0.60	1.25	0.69	NS
Kidney	0.12	0.61	0.12	0.61	0.12	0.61	NS
Peripheral vascular	1.54	1.25	1.58	1.26	1.53	1.24	NS
Joint/tendon	0.73	1.19	0.73	1.22	0.73	1.18	NS
Muscle	0.25	0.74	0.33	0.89	0.22	0.70	NS
Gastrointestinal	1.95	0.82	2.01	0.78	1.93	0.82	NS
Lung	1.38	1.11	1.56	1.08	1.34	1.12	1.19 (1.04, 1.37)	0.0084
Heart	0.50	1.00	0.60	1.12	0.48	0.97	NS
Physician global assessments of severity (range, 0-10)	2.77	2.26	2.99	2.31	2.71	2.24	NS
Patient global assessments of severity (range, 0-10)	3.64	2.61	3.66	2.67	3.63	2.60	NS

ISSN: 1478-6362